"Coronary heart disease is the biggest killer by far for people with Type 2 diabetes. Our findings suggest that not only does canagliflozin significantly reduce the risk of heart disease, it also has many other benefits too. Most other diabetes drugs work by managing insulin levels. "This really is a game changer in the treatment of Type 2 diabetes. It not only reduces the risk of heart disease, it also provides real protection against kidney decline which affects many people with diabetes," added Vlado Perkovic, Professor and Executive Director at The George Institute for Global Health.For the study, the team analysed more than 10,000 patients in 30 countries.

Source: Economic Times June 13, 2017 08:26 UTC